J-s S. Frenel

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Gineco group guidelines for clinical practice in gynecological cancer, Nice-Saint-Paul de Vence 2024-2025

Gineco group guidelines for clinical practice in gynecological cancer, Nice-Saint-Paul de Vence 2024-2025

Journal: Bulletin du cancer

Published: October 24, 2025

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: August 20, 2025

Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre-T-DM1 era cohort study.

Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre-T-DM1 era cohort study.

Journal: Cancer treatment and research communications

Published: August 04, 2025

Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.

Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 25, 2025

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.

Journal: ESMO open

Published: July 08, 2025

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.

Journal: Breast (Edinburgh, Scotland)

Published: April 29, 2025

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.

Journal: ESMO open

Published: March 24, 2025

Pocket guide based on the TNM and FIGO staging systems for classifying patients with locally advanced cervical cancer: a practical tool from the GINECO group for quick and easy management.

Pocket guide based on the TNM and FIGO staging systems for classifying patients with locally advanced cervical cancer: a practical tool from the GINECO group for quick and easy management.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 26, 2025

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Journal: Journal for immunotherapy of cancer

Published: November 25, 2024

Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer.

Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer.

Journal: ESMO open

Published: May 05, 2024

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Journal: British journal of cancer

Published: March 31, 2024

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.

Journal: Gynecologic oncology

Published: February 23, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026